Target intelligence / Profile preview

Activating transcription factor 5 (ATF5)

Target
ATF5
Molecular classification
Transcription factor, Basic leucine zipper (bZip) protein, cAMP response element-binding protein family
01

Overview

Activating transcription factor 5 (ATF5) is a member of the basic leucine zipper (bZip) family of transcription factors within the cAMP response element-binding protein lineage. ATF5 regulates gene expression in response to cellular stress and is involved in the control of cell survival, apoptosis, cell cycle, and differentiation, particularly within the central nervous system and in developing neural tissues. It is upregulated in a variety of cancers, where it promotes tumor growth and survival, and is implicated in oncogenesis and resistance to apoptosis. Targeting ATF5 with dominant-negative peptides has shown preclinical efficacy in inducing tumor regression, highlighting its potential as a therapeutic target in oncology. ATF5 also has roles in mitochondrial homeostasis, the unfolded protein response, and maintenance of centrosome integrity during cell division, linking its activity to genome stability and cancer biology.

Other names
ATF5ATF-5
02

Mechanism of action

Inhibition of ATF5's pro-survival transcriptional activity, leading to tumor regression and apoptosis in cancer cells

03

Biological functions

Transcriptional regulationCell survivalCell proliferationCell differentiationCell stress regulationMitochondrial unfolded protein responseCentrosome maturationRegulation of apoptosis
04

Disease associations

Cancer (notably glioblastoma, hepatocellular carcinoma, cervical cancer, other tumor types)Neurodevelopmental disordersOther diseases related to cellular stress or apoptosis
05

Safety considerations

Therapeutic targeting may impact normal tissue homeostasis and neurodevelopment given its role in stress response and neural progenitor maintenance
06

Interacting drugs

Dominant-negative ATF5 biologics (preclinical or experimental, e.g. CP-d/n-ATF5 peptide)
07

Biomarkers

High ATF5 expression may serve as a biomarker for cancers with poor prognosis or resistance to therapy

Beyond the preview

Go deeper on Activating transcription factor 5 (ATF5).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Activating transcription factor 5 (ATF5).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call